DexCom, Inc. (NASDAQ:DXCM) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other equities analysts have also recently weighed in on the company. Piper Jaffray Companies reissued an “overweight” rating and set a $78.00 price objective (down from $87.00) on shares of DexCom in a report on Wednesday. Zacks Investment Research raised DexCom from a “sell” rating to a “hold” rating in a report on Monday, August 14th. BMO Capital Markets reissued an “outperform” rating and set a $90.00 price objective (down from $105.00) on shares of DexCom in a report on Tuesday, August 8th. TheStreet raised DexCom from a “d” rating to a “c-” rating in a report on Wednesday, August 2nd. Finally, Stephens reissued an “overweight” rating and set a $83.00 price objective (down from $95.00) on shares of DexCom in a report on Wednesday, August 2nd. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $87.00.

Shares of DexCom (DXCM) traded up 0.58% on Friday, reaching $73.20. The company’s stock had a trading volume of 1,234,880 shares. The stock’s market cap is $6.34 billion. DexCom has a 12 month low of $57.68 and a 12 month high of $96.38. The firm’s 50-day moving average price is $70.65 and its 200-day moving average price is $74.91.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.07. The company had revenue of $170.60 million for the quarter, compared to analysts’ expectations of $166.54 million. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. DexCom’s revenue for the quarter was up 24.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.24) EPS. On average, analysts forecast that DexCom will post ($0.77) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/08/19/dexcom-inc-dxcm-raised-to-hold-at-bidaskclub.html.

In related news, CEO Kevin R. Sayer sold 6,000 shares of DexCom stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $69.07, for a total transaction of $414,420.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Steven Robert Pacelli sold 1,450 shares of DexCom stock in a transaction that occurred on Friday, June 23rd. The shares were sold at an average price of $78.19, for a total value of $113,375.50. The disclosure for this sale can be found here. Over the last quarter, insiders sold 33,726 shares of company stock worth $2,376,466. Corporate insiders own 1.70% of the company’s stock.

Several large investors have recently added to or reduced their stakes in DXCM. Independent Portfolio Consultants Inc. raised its stake in DexCom by 0.4% in the second quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock valued at $183,000 after buying an additional 9 shares in the last quarter. Bbva Compass Bancshares Inc. raised its stake in DexCom by 1.9% in the second quarter. Bbva Compass Bancshares Inc. now owns 3,670 shares of the medical device company’s stock valued at $268,000 after buying an additional 69 shares in the last quarter. Mn Services Vermogensbeheer B.V. raised its stake in DexCom by 3.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,254 shares of the medical device company’s stock valued at $179,000 after buying an additional 83 shares in the last quarter. Public Employees Retirement Association of Colorado raised its stake in DexCom by 0.4% in the second quarter. Public Employees Retirement Association of Colorado now owns 18,613 shares of the medical device company’s stock valued at $1,362,000 after buying an additional 83 shares in the last quarter. Finally, King Luther Capital Management Corp raised its stake in DexCom by 0.7% in the first quarter. King Luther Capital Management Corp now owns 12,105 shares of the medical device company’s stock valued at $1,026,000 after buying an additional 90 shares in the last quarter.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.